Viral suppression remains the main objective of ART (antiretroviral therapy) for HIV-infected individuals. However, achieving an undetectable viral load continues to be a challenge for many individuals. Aong the obstacles that hinder ART success, poor drug adherence is responsible for most episodes of failure to achieve and maintain virologic suppression. Up to 25% of individuals on chronic ART may experience episodes episodes of non-adherence and only 51% of HIV-infected adults in the US are virally supressed (1). This is a suboptimal outcome from both an individual and public health perspective. Thus, improving ART adherence remains of critical importance in HIV treatment.
